🫁 Asthma Therapeutic Vaccine Tracker Dashboard

Updated July 2026. This page tracks therapeutic biologics — there is no true "asthma vaccine" in clinical development. The severe asthma biologic landscape remains dominated by five FDA-approved products: omalizumab (anti-IgE, Xolair), mepolizumab (anti-IL-5, Nucala), benralizumab (anti-IL-5R, Fasenra), dupilumab (anti-IL-4Rα, Dupixent), and tezepelumab (anti-TSLP, Tezspire). Recent developments: depemokimab (long-acting anti-IL-5, GSK) — FDA under review with positive Phase 3 SWIFT-1/SWIFT-2 trials; itepekimab (anti-IL-33, Regeneron/Sanofi) — Phase 3 AERIFY trials.

Comprehensive tracking of asthma therapeutic vaccine development including biologics (anti-IgE, anti-IL-5, anti-IL-4/13, anti-TSLP), allergen immunotherapy for allergic asthma, and novel disease-modifying approaches. Asthma affects 25 million US adults (8%), 262 million globally with 262,000 deaths annually. Chronic inflammatory airway disease causing wheezing, shortness of breath, chest tightness. Immunotherapy and biologics target underlying immune dysregulation - IgE-mediated Type 2 inflammation, eosinophilic pathways, Th2 cytokines. Multiple FDA-approved biologics revolutionizing severe asthma management. Allergen immunotherapy prevents asthma development in allergic rhinitis patients. Next-generation vaccines targeting airway remodeling, epithelial dysfunction. Complementary to inhaled corticosteroids and bronchodilators. Disease-modifying potential with monitoring tools.

⚠️ MAJOR GLOBAL HEALTH BURDEN:

Asthma affects 25 million US adults (8%), 262 million globally. Leading chronic disease in children - 6 million US kids affected. 262,000 deaths annually worldwide (mostly preventable with proper treatment). 1.6 million ER visits/year US, 439,000 hospitalizations, 3,600 deaths. Disproportionately affects minorities and low-income communities (environmental exposures, access barriers). $81.9 billion annual US costs ($50.3B direct medical, $31.6B lost productivity). Quality of life severely impaired - missed school/work (13.8M days/year), sleep disruption, exercise limitation, psychological burden (anxiety about attacks). Current medications (inhalers, steroids) control symptoms but don't modify disease. Biologics offer disease modification for severe asthma. Immunotherapy prevents asthma in at-risk patients - true prevention strategy.

🔬 Clinical Trial & News Resources:

📊 View all asthma immunotherapy trials on ClinicalTrials.gov →
🌍 American Lung Association - Asthma →
🌍 AAAAI Asthma Resources →
🌍 NHLBI Asthma Information →
📰 Latest Asthma Immunotherapy News (Google) →

Asthma Immunotherapy by Development Phase

25M

US Adults with Asthma

262K

Annual Global Deaths

$82B

Annual US Costs

✅ FDA-Approved Biologics - Revolutionary Treatment

Anti-IgE Biologics

Blocking allergic cascade at source

FDA Approved

Product Xolair (omalizumab)

Manufacturer Genentech/Novartis

Target IgE antibodies

Approved 2003 (first biologic for asthma)

Efficacy 50% exacerbation reduction

Details: Xolair (omalizumab) first biologic approved for asthma (2003). Monoclonal antibody binding free IgE, preventing attachment to mast cells/basophils. Reduces IgE-mediated inflammation - cornerstone of allergic (Type 2) asthma. Subcutaneous injection every 2-4 weeks. Approved for moderate-severe allergic asthma age 6+, chronic urticaria, nasal polyps. Efficacy: 50% reduction in exacerbations, improved lung function (FEV1 +10%), reduced oral steroid use, better quality of life. Mechanism: Blocks IgE → reduced mast cell degranulation → less histamine, leukotrienes → reduced airway inflammation and hyperresponsiveness. Requires elevated IgE levels (30-700 IU/mL) and positive allergy testing for approval. Cost: $30,000-40,000/year. Revolutionized severe asthma treatment - first targeted therapy beyond steroids/bronchodilators.

Anti-IL-5 Biologics

Targeting eosinophilic inflammation

FDA Approved (3)

Products: (1) Nucala (mepolizumab) - GSK, anti-IL-5, 2015 approval, SC injection monthly, 50% exacerbation reduction in eosinophilic asthma (blood eosinophils ≥150-300). (2) Cinqair (reslizumab) - Teva, anti-IL-5, IV infusion monthly, eosinophils ≥400 required. (3) Fasenra (benralizumab) - AstraZeneca, anti-IL-5 receptor alpha, most potent - depletes eosinophils via antibody-dependent cell cytotoxicity (ADCC), every 8 weeks after loading, 50-70% exacerbation reduction, superior steroid-sparing.

Mechanism: IL-5 key cytokine for eosinophil survival, maturation, activation. Eosinophilic asthma (40-50% of severe asthma) characterized by airway eosinophilia driving inflammation, mucus production, remodeling. Blocking IL-5/IL-5R → eosinophil depletion → reduced airway inflammation. Best in patients with blood eosinophils ≥300 cells/μL, history of exacerbations. Game-changing for eosinophilic phenotype - some patients achieve near-remission.

Anti-IL-4/IL-13 Biologic

Dual pathway blockade - Type 2 inflammation

FDA Approved

Product Dupixent (dupilumab)

Manufacturer Sanofi/Regeneron

Target IL-4Rα (blocks IL-4 and IL-13)

Efficacy 70% exacerbation reduction in Type 2

Details: Dupixent (dupilumab) blocks IL-4 receptor alpha, inhibiting BOTH IL-4 and IL-13 signaling - dual Type 2 cytokine blockade. Approved 2018 for moderate-severe asthma with Type 2 inflammation (elevated eosinophils ≥150 or FeNO ≥25 ppb). Also approved: atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis (most indications of any biologic). SC injection every 2 weeks. Efficacy: 70% exacerbation reduction in Type 2-high patients, improved lung function (+200-300 mL FEV1), remarkable steroid-sparing (80% reduction oral corticosteroids), improved quality of life. Mechanism: IL-4/IL-13 drive Type 2 inflammation - IgE class switching, eosinophil recruitment, mucus hypersecretion, airway remodeling. Blocking both → comprehensive Type 2 suppression. Broad efficacy across Type 2 inflammatory diseases. Becoming first-line biologic for many due to broad applicability, excellent efficacy, favorable safety (conjunctivitis main side effect). Cost: $37,000/year.

Anti-TSLP Biologic

Upstream Type 2 inflammation blocker

FDA Approved

Product Tezspire (tezepelumab)

Manufacturer AstraZeneca/Amgen

Target TSLP (thymic stromal lymphopoietin)

Unique Feature Works regardless of biomarkers

Details: Tezspire (tezepelumab) approved 2021, newest asthma biologic. Targets TSLP (thymic stromal lymphopoietin) - alarmin released by airway epithelial cells in response to allergens, pollutants, viruses, initiating Type 2 inflammation cascade. TSLP drives DC activation → Th2 differentiation → IL-4/IL-5/IL-13 production → eosinophils, IgE, inflammation. Blocking TSLP = upstream intervention, broader than targeting individual cytokines. SC injection every 4 weeks. Efficacy: 56% exacerbation reduction in all-comers (not requiring Type 2 biomarkers!), 70% in Type 2-high. REVOLUTIONARY: First biologic effective regardless of eosinophils/IgE/FeNO - expands treatment to non-Type 2 asthma patients previously without biologic options. Mechanism advantages: Broader inflammation suppression (Type 2 AND non-Type 2 pathways), epithelial-focused (addresses airway barrier dysfunction), effective in mixed/difficult-to-classify phenotypes. Game-changer for severe asthma classification - don't need biomarkers to predict response.

🌿 Allergen Immunotherapy - Disease Prevention

Allergen Immunotherapy for Allergic Asthma

Prevents asthma development - true disease modification

FDA Approved

Background: 60% of asthma has allergic component (aeroallergens: dust mites, pollen, mold, pets). Allergic rhinitis patients 3x risk of developing asthma ("one airway, one disease" - united airway concept). Allergen immunotherapy (SCIT/SLIT) for rhinitis PREVENTS asthma development.

Evidence - Asthma Prevention: Landmark PAT study (Preventive Allergy Treatment): Children with allergic rhinitis randomized to grass SCIT vs. control. Results: 60% reduction in asthma development at 5 years, 45% reduction at 10 years post-treatment. Other studies: Dust mite SCIT/SLIT reduces asthma symptoms 30-40% in allergic asthma, improves lung function, reduces medication use. SLIT tablets (Grastek, Odactra) show asthma improvement in secondary endpoints of allergy trials.

Mechanism: Immune tolerance induction (same as allergy) - Th2 → Th1/Treg shift, reduced IgE, increased IgG4 blocking antibodies. In asthma: Reduces allergen-triggered bronchoconstriction, airway hyperresponsiveness, eosinophilic inflammation. Prevents progression of atopic march (rhinitis → asthma). Best efficacy: (1) Allergic asthma with confirmed allergen sensitization, (2) Mild-moderate asthma (controlled with inhalers), (3) Children/young adults (before irreversible remodeling), (4) Preventive use in high-risk rhinitis patients.

Limitations: Not for severe uncontrolled asthma (SCIT contraindicated - anaphylaxis risk during exacerbation). Adjunct to inhaled steroids, not replacement. Modest benefit in established asthma (30-40% improvement) vs. prevention (60% asthma reduction). Takes months-years for full effect. Best positioned as PREVENTION strategy in allergic rhinitis to stop atopic march, rather than primary treatment for established asthma.

🧬 Phase 3 & Phase 2 Development

Anti-Alarmin Biologics (IL-33, IL-25)

Targeting epithelial-derived inflammatory signals

Phase 3

Candidates Itepekimab (anti-IL-33), Others

Developers Sanofi/Regeneron, AstraZeneca

Rationale Upstream epithelial targets

Concept: IL-33 and IL-25 are alarmins released by damaged airway epithelium (pollution, allergens, viruses). Initiate Type 2 inflammation like TSLP but through different receptors (ST2 for IL-33). Blocking alarmins = upstream intervention. Itepekimab (anti-IL-33, Sanofi) Phase 3 in asthma and COPD. Early data: 60% exacerbation reduction, improved lung function. May work in viral-triggered asthma (IL-33 released during viral infections). Potential advantage over TSLP: IL-33 more prominent in certain exacerbation phenotypes.

Phase 2 Candidates (3)

Novel mechanisms

Phase 2

Approaches: (1) Anti-ST2 (IL-33 receptor blocker) - alternative to anti-IL-33; (2) Anti-prostaglandin D2 - targeting mast cell/eosinophil chemoattractant; (3) Chymase inhibitors - mast cell protease driving inflammation and remodeling.

🧪 Phase 1 & Preclinical - Next Generation

Phase 1 Approaches (4)

Novel pathways

Phase 1

Targets: (1) Anti-OX40L - blocks T-cell co-stimulation; (2) Anti-CCR3 - eosinophil chemokine receptor; (3) Inhaled biologics - local delivery to airways avoiding systemic exposure; (4) Bispecific antibodies - simultaneously targeting two cytokines (IL-4/IL-5, IL-13/IL-33).

Preclinical Platforms (5)

Cutting-edge concepts

Preclinical

Technologies: (1) mRNA vaccines - encoding hypoallergens or tolerogenic antigens; (2) Gene therapy - correcting epithelial barrier dysfunction; (3) Microbiome modulation - restoring healthy airway microbiome reducing inflammation; (4) Anti-remodeling agents - preventing/reversing airway structural changes (collagen deposition, smooth muscle hyperplasia); (5) Regenerative medicine - stem cell therapy for airway repair.

Institutions: NIH/NHLBI, UCSF, Imperial College London, Stanford

📊 Disease Burden & Future Outlook

Asthma - Chronic Airway Inflammation

Epidemiology: 25 million US adults (8%), 262 million globally, 6 million US children. Most common chronic disease in children. 262,000 deaths annually worldwide (mostly preventable). 1.6M ER visits/year US, 439,000 hospitalizations, 3,600 deaths. Higher prevalence: minorities (11% Black vs. 8% white), low-income, urban areas (air pollution, allergen exposure, healthcare access). Increasing prevalence: doubled since 1980 (hygiene hypothesis, air pollution, obesity, climate change).

Pathophysiology: Chronic airway inflammation → bronchial hyperresponsiveness, reversible obstruction, remodeling. Key features: (1) Inflammation - eosinophils, mast cells, Th2 cells infiltrate airways; (2) Bronchoconstriction - smooth muscle contraction from histamine, leukotrienes; (3) Mucus hypersecretion - obstructs airways; (4) Remodeling - chronic inflammation → irreversible changes (basement membrane thickening, collagen deposition, smooth muscle hyperplasia). Triggers: Allergens, viral infections, exercise, cold air, irritants, stress. Symptoms: Wheezing, shortness of breath, chest tightness, cough (worse at night).

Phenotypes: Allergic asthma (60%) - aeroallergen-driven, elevated IgE, eosinophilic, childhood onset, responds to immunotherapy/anti-IgE. Eosinophilic asthma (40-50% severe) - elevated eosinophils, adult-onset, steroid-dependent, responds to anti-IL-5/IL-4/13. Non-Type 2 asthma (20-30%) - neutrophilic or paucigranulocytic, poor steroid response, limited biologic options (except Tezspire). Exercise-induced (70% have) - bronchoconstriction with exertion. Aspirin-exacerbated (AERD) - nasal polyps, aspirin sensitivity, severe. Occupational (10-15%) - workplace exposures.

Treatment Paradigm - Stepwise Approach

Traditional Therapy (Steps 1-4): Step 1: PRN SABA (albuterol). Step 2: Low-dose ICS. Step 3: Low-dose ICS/LABA. Step 4: Medium-high dose ICS/LABA ± LAMA. Goals: Symptom control, prevent exacerbations, maintain lung function, minimize medication side effects.

Severe Asthma (Step 5): Persistent symptoms despite high-dose ICS/LABA or requiring oral corticosteroids. 5-10% of asthma but 50% of costs. Biologics revolutionized management: Phenotype-directed selection (IgE → Xolair, eosinophils → Nucala/Fasenra, Type 2 → Dupixent, any → Tezspire). 50-70% exacerbation reduction, steroid-sparing, improved quality of life. Game-changing but expensive ($30-40,000/year) - cost-effectiveness debated.

Limitations: No cure - chronic management. Inhaled steroids: Side effects (thrush, dysphonia, growth suppression children, long-term bone loss). Biologics: Not universal responders (30-40% don't achieve target response), expensive, require injections/infusions, long-term safety unknown (most <10 years data). Remodeling irreversible once occurred. Non-Type 2 asthma (20-30%) - limited options until Tezspire.

Future of Asthma Treatment 2025-2040

Near-Term (2025-2030): Oral biologics (currently injectable/IV) - improving convenience. Combination biologics (dual IL-4/IL-5, IL-33/TSLP) - synergistic effects. Biomarker-guided therapy widespread - blood eosinophils, FeNO, periostin guiding biologic selection. Long-acting biologics (quarterly dosing) - improving adherence. Inhaled biologics - local delivery, lower cost. More non-Type 2 options (anti-IL-33, IL-25). Allergen immunotherapy integrated into asthma management (prevention focus). Lower biologic costs (biosimilars, competition).

Mid-Term (2030-2040): Preventive vaccines - high-risk children (family history, atopic dermatitis, allergies) vaccinated to prevent asthma development. Microbiome therapies - probiotic/prebiotic interventions restoring healthy airway flora. Gene therapy - correcting epithelial dysfunction, reducing Type 2 inflammation genetically. Anti-remodeling agents - reversing structural changes (regenerative medicine). mRNA vaccines - personalized allergen-specific tolerance. Cure-focused approaches - rather than chronic management. Artificial intelligence - predicting exacerbations, optimizing therapy, phenotyping patients.

Vision: Asthma deaths eliminated (currently 3,600/year US). Severe asthma controlled with biologics (no more oral steroids, hospitalizations). Preventive vaccination reduces asthma incidence 50%+ (stopping atopic march). Children with allergic rhinitis routinely receive immunotherapy preventing asthma. Personalized medicine - genetic/biomarker profiling guides optimal therapy. Remodeling prevented/reversed - preserving lung function lifelong. Asthma transitions from chronic limitation to manageable condition like well-controlled diabetes - minimal symptoms, normal life expectancy, no disability.